New versions of drugs like Wegovy, Ozempic, Mounjaro and Zepbound, including pills, will be easier to take, more effective ...

In a 71-week, double-blind study, Nova Nordisk—creators of the popular weight loss drug Wegovy—says their oral semaglutide ...

Obesity is one of the biggest barriers preventing patients with end-stage kidney disease from receiving a life-saving kidney ...

If you've tried the usual weight loss approaches-eating well, moving your body and tracking what you consume-but you're still ...

If you plan to wean yourself off weight loss jabs then consider this your expert guide to doing so sustainably ...

Unsupervised GLP-1 use rises in India as structured, doctor-led platforms like Early.Fit push for safer, science-backed ...

Weight-loss drugs are booming (1) and you’ve probably heard of them: Wegovy, Ozempic, Mounjaro, Zepbound. These GLP-1 medications are helping Americans slim down and manage diabetes — and in some ...

Three new Cochrane reviews find evidence that GLP-1 drugs lead to clinically meaningful weight loss, though industry-funded studies raise concerns. Three new reviews from Cochrane have found that ...

Study finds GLP-1 drugs may reduce risk of more than a dozen cancers, offering hope in Louisiana where obesity-related cancer ...

Weight-loss drugs are booming (1) and you’ve probably heard of them: Wegovy, Ozempic, Mounjaro, Zepbound. These GLP-1 ...

Drugmaker Eli Lilly said it would soon start late-stage trials for eloralintide, a drug mimicking the pancreatic hormone amylin that slows digestion and reduces hunger.

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh. Who is winning?